Abbott Laboratories

Abbott Reports 12-Month Positive Results From VOLT-AF IDE Study, Shares Rise 0.60%

雅培

Abbott Laboratories' 15-min chart shows MACD Death Cross, KDJ Death Cross.

Abbott Laboratories Director Starks Buys 4967 Shares at $109.14/Share on 2026-02-04.

Abbott Presents Positive Volt PFA System Results at AF Symposium

Goldman Sachs

5 Goldman Sachs Top Picks for High Dividend and Upside Potential

Catalyst<ul> <li>Most analysts rate ABT Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a weak state, and we need to pay attention to the risk of decline.</li> <li>Bearish signals are obviously dominant in technical analysis.</li> <li>Net outflow trends by large and medium order sizes indicate selling pressure.</li></ul>

Key Factors

Abbott announced positive 12-month results from its VOLT-AF IDE study, reinforcing the safety and efficacy of its Volt Pulsed Field Ablation System. Abbott secured FDA approval and CE Mark for its Volt Pulsed Field Ablation System and has begun commercial cases in the U.S. Abbott's Director Daniel J. Starks purchased 4,967 shares at $109.14 per share and 5,033 shares at $108.33 per share on February 4, 2026. Abbott's TactiFlex Duo Ablation Catheter demonstrated safety and efficacy in reducing AFib episodes, with data presented at the AF Symposium and published in JACC: Clinical Electrophysiology. Wall Street analysts rate Abbott Laboratories as a "Strong Buy" with an average price target of $138.76, indicating a potential 26.83% upside.

Recent Updates

ABT News